hotspot -WSS

hotspot

author：leisure time 2025-08-11 10:53:45 - browse：5

Jeremey Wyatt ActiGraph

As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Congress must reauthorize a committee to support older Americans

WSS

Global cancer cases to surge 77% by 2050, WHO report says

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Devoted Health’s losses in Medicare Advantage persist

World's first CRISPR

PBM reforms clear House panel

knowledge

hotspot

leisure time

What does generative AI mean for health care? We asked experts

Unique patient identifier: Experts argue the benefits, pitfalls

At least 13 dead in Texas as scorching temps continue

AI gets buy

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

How to save PrEP access — and even expand it

AstraZeneca stays mum on Medicare drug pricing negotiations

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The Biogen Aduhelm mess could happen again

entertainment

Bernie brings in new pharma CEOs to talk drug prices

AI gets buy

The Biogen Aduhelm mess could happen again

A single Democrat is willing to weaken Medicare negotiation power

Bernie brings in new pharma CEOs to talk drug prices

Wegovy, Zepbound and weight loss drugs that preserve muscle

focus

explore

entertainment

hotspot